Clinical Trials Logo

Filter by:
NCT ID: NCT03215030 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

iinnovate-1
Start date: October 4, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants. Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa. Participants will receive modakafusp alfa at one of two doses which will be given through a vein.

NCT ID: NCT03212469 Active, not recruiting - Lung Cancer Clinical Trials

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

ABIMMUNE
Start date: June 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.

NCT ID: NCT03211247 Active, not recruiting - Peanut Allergy Clinical Trials

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

EPITOPE
Start date: July 31, 2017
Phase: Phase 3
Study type: Interventional

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

NCT ID: NCT03210675 Active, not recruiting - Down Syndrome Clinical Trials

Early Detection and Treatment of Respiratory Sleep Disorders in Children With Down Syndrome

RESPIRE21
Start date: July 31, 2017
Phase: N/A
Study type: Interventional

Interventional, comparative, open label, single-center study to demonstrate that an early (from 6 months of age) and systematic (every 6 months) screening of Obstructive Sleep Apnea (OSA) by polysomnography (PSG) in children with Down Syndrome during the first 3 years of life is associated with an improved neurocognitive development at the age of 3 years.

NCT ID: NCT03209102 Active, not recruiting - Clinical trials for Borderline Personality Disorder

Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder

ADOLIMIS
Start date: October 4, 2017
Phase: Phase 2
Study type: Interventional

This study aims to better understand the behavioral, neurobiological and hormonal underpinnings of stress and reward reactivity of adolescents suffering from borderline personality disorder compared to healthy adolescents by a multimodal approach based on clinical assessments, structural and functional mri and experimental acute stress exposure.

NCT ID: NCT03203031 Active, not recruiting - Postoperative Pain Clinical Trials

Postoperative Pain in Neonates After Abdominal Surgery Using Quadratus Lumborum Block

Start date: June 30, 2017
Phase:
Study type: Observational

Postoperative pain scores and analgesic requirements will be evaluated in neonates after abdominal surgery, with regional quadratus lumborum block performed at the beginning of the procedure.

NCT ID: NCT03201965 Active, not recruiting - Amyloidosis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Start date: October 5, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

NCT ID: NCT03200678 Active, not recruiting - Muscle Weakness Clinical Trials

WEakness and Atrophy: isoKinetic With Surface Electromyography Assessment in ACL Surgery

WEAKNESS
Start date: May 7, 2018
Phase: N/A
Study type: Interventional

An assessment of the effect of surgical anterior cruciate ligament (ACL) on thigh muscles is critical to the improvement of knee rehabilitation and preservation. However, if a large number of studies had rated surgical technics, giving high results level for ACL reconstruction (ACLR), muscle recovery is still conditioning functional success. Furthermore there is no consensus about criteria in return to sport. The aim of this exploratory study is to quantify the mechanisms of neuromuscular adaptation of muscle thigh after ACL surgery.

NCT ID: NCT03200353 Active, not recruiting - Ulcer Venous Clinical Trials

Evaluation of Sores Treatment by Oxygenotherapy

Start date: April 10, 2017
Phase: N/A
Study type: Interventional

Patient with chronic wounds are selected to receive NATROX system ; it's a continous diffusion of oxygen therapy delivery system. This one is put on the wound during a consultation at the hospital and will be followed in home medical care. Every 2 days a nurse renew the application at home and patient recharge the system with oxygen every day. The complete treatment is prescribe for 4 weeks and at the end patient comes to hospital to have a consultation with the doctor.

NCT ID: NCT03199469 Active, not recruiting - Clinical trials for X-Linked Myotubular Myopathy

Gene Transfer Clinical Study in X-Linked Myotubular Myopathy

ASPIRO
Start date: August 2, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study to evaluate the safety and efficacy of AT132 in subjects with X-Linked Myotubular Myopathy aged less than 5 years old. Subjects will receive a single dose of AT132 and will be followed for safety and efficacy for 10 years